Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 73

1.

IFNγ producing CD8+ T cells modified to resist major immune checkpoints induce regression of MHC class I-deficient melanomas.

Buferne M, Chasson L, Grange M, Mas A, Arnoux F, Bertuzzi M, Naquet P, Leserman L, Schmitt-Verhulst AM, Auphan-Anezin N.

Oncoimmunology. 2015 Mar 6;4(2):e974959. eCollection 2015 Feb.

2.

Brucella β 1,2 cyclic glucan is an activator of human and mouse dendritic cells.

Martirosyan A, Pérez-Gutierrez C, Banchereau R, Dutartre H, Lecine P, Dullaers M, Mello M, Salcedo SP, Muller A, Leserman L, Levy Y, Zurawski G, Zurawski S, Moreno E, Moriyón I, Klechevsky E, Banchereau J, Oh S, Gorvel JP.

PLoS Pathog. 2012;8(11):e1002983. doi: 10.1371/journal.ppat.1002983. Epub 2012 Nov 15.

3.

Activated STAT5 promotes long-lived cytotoxic CD8+ T cells that induce regression of autochthonous melanoma.

Grange M, Buferne M, Verdeil G, Leserman L, Schmitt-Verhulst AM, Auphan-Anezin N.

Cancer Res. 2012 Jan 1;72(1):76-87. doi: 10.1158/0008-5472.CAN-11-2187. Epub 2011 Nov 7.

4.

Disrupted lymph node and splenic stroma in mice with induced inflammatory melanomas is associated with impaired recruitment of T and dendritic cells.

Soudja SM, Henri S, Mello M, Chasson L, Mas A, Wehbe M, Auphan-Anezin N, Leserman L, Van den Eynde B, Schmitt-Verhulst AM.

PLoS One. 2011;6(7):e22639. doi: 10.1371/journal.pone.0022639. Epub 2011 Jul 21.

5.

The Gregoriadyssey: from smetic mesophases to liposomal drug carriers, a personal reflection of Gregory Gregoriadis.

Leserman L.

J Drug Target. 2008 Aug;16(7):525-8. doi: 10.1080/10611860802228400. No abstract available.

PMID:
18686121
6.

ZAP-70 restoration in mice by in vivo thymic electroporation.

Irla M, Saade M, Kissenpfennig A, Poulin LF, Leserman L, Marche PN, Jouvin-Marche E, Berger F, Nguyen C.

PLoS One. 2008 Apr 30;3(4):e2059. doi: 10.1371/journal.pone.0002059.

7.

CD8 T cell help for innate antitumor immunity.

Shanker A, Verdeil G, Buferne M, Inderberg-Suso EM, Puthier D, Joly F, Nguyen C, Leserman L, Auphan-Anezin N, Schmitt-Verhulst AM.

J Immunol. 2007 Nov 15;179(10):6651-62.

8.

Mature DC from skin and skin-draining LN retain the ability to acquire and efficiently present targeted antigen.

Henri S, Siret C, Machy P, Kissenpfennig A, Malissen B, Leserman L.

Eur J Immunol. 2007 May;37(5):1184-93.

9.

CD4 T cell help is required for primary CD8 T cell responses to vesicular antigen delivered to dendritic cells in vivo.

Serre K, Giraudo L, Siret C, Leserman L, Machy P.

Eur J Immunol. 2006 Jun;36(6):1386-97.

10.

Dynamics and function of Langerhans cells in vivo: dermal dendritic cells colonize lymph node areas distinct from slower migrating Langerhans cells.

Kissenpfennig A, Henri S, Dubois B, Laplace-Builhé C, Perrin P, Romani N, Tripp CH, Douillard P, Leserman L, Kaiserlian D, Saeland S, Davoust J, Malissen B.

Immunity. 2005 May;22(5):643-54.

11.

Liposomes as protein carriers in immunology.

Leserman L.

J Liposome Res. 2004;14(3-4):175-89. Review.

PMID:
15676125
12.

Liposomes targeted to Fc receptors for antigen presentation by dendritic cells in vitro and in vivo.

Serre K, Giraudo L, Leserman L, Machy P.

Methods Enzymol. 2003;373:100-18. No abstract available.

PMID:
14714399
13.

MHC class II-peptide complexes in dendritic cell lipid microdomains initiate the CD4 Th1 phenotype.

Buatois V, Baillet M, Bécart S, Mooney N, Leserman L, Machy P.

J Immunol. 2003 Dec 1;171(11):5812-9.

14.

Dendritic cells capture and efficiently present antigen encapsulated in liposomes to T cells in vivo.

Serre K, Giraudo L, Henri S, Machy P, Leserman L.

J Liposome Res. 2003 Feb;13(1):21-3. Review. No abstract available.

PMID:
12725723
15.

Virosome-mediated delivery of protein antigens to dendritic cells.

Bungener L, Serre K, Bijl L, Leserman L, Wilschut J, Daemen T, Machy P.

Vaccine. 2002 May 22;20(17-18):2287-95.

PMID:
12009284
17.

[Immunotargeting of tumors: state of the art and prospects in 2000].

Pèlegrin A, Xavier F, Barbet J, Bartholeyns J, Baty D, Buchegger F, Chatal JF, Dufief F, Gurreau D, Gruaz-Guyon A, Lamotte D, Leserman L, Mach JP, Robert B, Saccavini JC, Teillaud JL, Teulon I.

Bull Cancer. 2000 Nov;87(11):777-91. Review. French.

19.

Presentation of antigens internalized through the B cell receptor requires newly synthesized MHC class II molecules.

Forquet F, Barois N, Machy P, Trucy J, Zimmermann VS, Leserman L, Davoust J.

J Immunol. 1999 Mar 15;162(6):3408-16.

20.

Engagement of B cell receptor regulates the invariant chain-dependent MHC class II presentation pathway.

Zimmermann VS, Rovere P, Trucy J, Serre K, Machy P, Forquet F, Leserman L, Davoust J.

J Immunol. 1999 Mar 1;162(5):2495-502.

21.

Efficient presentation of multivalent antigens targeted to various cell surface molecules of dendritic cells and surface Ig of antigen-specific B cells.

Serre K, Machy P, Grivel JC, Jolly G, Brun N, Barbet J, Leserman L.

J Immunol. 1998 Dec 1;161(11):6059-67.

22.
23.

Influence of MHC class I molecules on T-cell proliferation induced by CD3 or Thy-1 stimulation.

Amirayan N, Furrie E, Deleuil F, Mellor A, Leserman L, Machy P.

Immunology. 1995 Sep;86(1):71-8.

24.

Antisense oligonucleotides in solution or encapsulated in immunoliposomes inhibit replication of HIV-1 by several different mechanisms.

Zelphati O, Imbach JL, Signoret N, Zon G, Rayner B, Leserman L.

Nucleic Acids Res. 1994 Oct 11;22(20):4307-14.

25.
26.

Endocytosis and presentation of liposome-associated antigens by B cells.

Grivel JC, Crook K, Leserman L.

Immunomethods. 1994 Jun;4(3):223-8. Review.

PMID:
7820453
27.

Inhibition of HIV-1 replication in cultured cells with phosphorylated dideoxyuridine derivatives encapsulated in immunoliposomes.

Zelphati O, Degols G, Loughrey H, Leserman L, Pompon A, Puech F, Maggio AF, Imbach JL, Gosselin G.

Antiviral Res. 1993 Jul;21(3):181-95.

PMID:
8215297
28.

Rapid induction of anti-idiotypic responses to unmodified monoclonal antibodies from syngeneic mice following primary immunization.

Grivel JC, Ferrier P, Renard N, Jolly G, Jarry T, Leserman L.

J Immunol Methods. 1993 Feb 3;158(2):173-82.

PMID:
8429222
29.

Specific in vitro labeling of cells with a fluorine-19 probe encapsulated in antibody-targeted liposomes: a F-19 NMR spectroscopy study.

Vion-Dury J, Machy P, Confort-Gouny S, Leserman L, Cozzone PJ.

Magn Reson Med. 1993 Feb;29(2):252-5.

PMID:
8429791
30.

Inhibition of HIV-1 replication in cultured cells with antisense oligonucleotides encapsulated in immunoliposomes.

Zelphati O, Zon G, Leserman L.

Antisense Res Dev. 1993 Winter;3(4):323-38.

PMID:
8155974
31.

Free and liposome-encapsulated double-stranded RNAs as inducers of interferon, interleukin-6, and cellular toxicity.

Milhaud PG, Machy P, Colote S, Lebleu B, Leserman L.

J Interferon Res. 1991 Oct;11(5):261-5.

PMID:
1774464
32.

CD4 and CD7 molecules as targets for drug delivery from antibody bearing liposomes.

Suzuki H, Zelphati O, Hildebrand G, Leserman L.

Exp Cell Res. 1991 Mar;193(1):112-9.

PMID:
1704842
33.

Cordycepin analogues of 2',5'-oligoadenylate inhibit human immunodeficiency virus infection via inhibition of reverse transcriptase.

Müller WE, Weiler BE, Charubala R, Pfleiderer W, Leserman L, Sobol RW, Suhadolnik RJ, Schröder HC.

Biochemistry. 1991 Feb 26;30(8):2027-33.

PMID:
1705437
34.

Inhibition of expression of human immunodeficiency virus-1 in vitro by antibody-targeted liposomes containing antisense RNA to the env region.

Renneisen K, Leserman L, Matthes E, Schröder HC, Müller WE.

J Biol Chem. 1990 Sep 25;265(27):16337-42.

35.

Endocytosis and recycling of MHC-encoded class II molecules by mouse B lymphocytes.

Machy P, Bizozzero JP, Reggio H, Leserman L.

J Immunol. 1990 Sep 1;145(5):1350-5.

PMID:
2384661
36.

Antibody-targeted liposomes containing oligodeoxyribonucleotides complementary to viral RNA selectively inhibit viral replication.

Leonetti JP, Machy P, Degols G, Lebleu B, Leserman L.

Proc Natl Acad Sci U S A. 1990 Apr;87(7):2448-51.

37.

Fishy tale.

Leserman L.

Nature. 1990 Jan 18;343(6255):202. No abstract available.

PMID:
2300160
38.

Targeted liposomes and intracellular delivery of macromolecules.

Leserman L, Machy P, Leonetti JP, Milhaud PG, Degols G, Lebleu B.

Prog Clin Biol Res. 1990;343:95-102. Review. No abstract available.

PMID:
2198587
39.
40.

Positive and negative liposome-based immunoselection techniques.

Leserman L, Langlet C, Schmitt-Verhulst AM, Machy P.

Methods Cell Biol. 1989;32:447-71. Review. No abstract available.

PMID:
2691860
41.

Inhibition of cell proliferation with antibody-targeted liposomes containing methotrexate-gamma-dimyristoylphosphatidylethanolamine.

Noé C, Hernandez-Borrell J, Kinsky SC, Matsuura E, Leserman L.

Biochim Biophys Acta. 1988 Dec 22;946(2):253-60.

PMID:
3207742
42.

A tissue-specific DNase I-hypersensitive site in a class II A alpha gene is under trans-regulatory control.

Liou HC, Polla BS, Aragnol D, Leserman LD, Griffith IJ, Glimcher LH.

Proc Natl Acad Sci U S A. 1988 Apr;85(8):2738-42.

43.

Role of Ti/CD3, Thy-1, and Ly-6 in cytolytic T-cell activation analyzed with Ti loss variants.

Langlet C, Guimezanes A, Kaldy P, Boyer C, Buferne M, Poenie M, Tsien R, Leo O, Bluestone J, Leserman L, et al.

Ann N Y Acad Sci. 1988;532:33-43. No abstract available.

PMID:
2902820
44.

Pleiotropic loss of activation pathways in a T-cell receptor alpha-chain deletion variant of a cytolytic T-cell clone.

Schmitt-Verhulst AM, Guimezanes A, Boyer C, Poenie M, Tsien R, Buferne M, Hua C, Leserman L.

Nature. 1987 Feb 12-18;325(6105):628-31.

PMID:
2880301
45.
46.

Endocytosis of MHC molecules by B cell-B lymphoma and B cell-T lymphoma hybrids.

Aragnol D, Malissen B, Schiff C, Piron MA, Leserman LD.

J Immunol. 1986 Nov 15;137(10):3347-53.

PMID:
3095429
47.

The introversion of the immune response.

Leserman L.

Immunol Today. 1986 Jun;7(6):162. doi: 10.1016/0167-5699(86)90164-7. No abstract available.

PMID:
25290198
49.

Immune clearance of liposomes inhibited by an anti-Fc receptor antibody in vivo.

Aragnol D, Leserman LD.

Proc Natl Acad Sci U S A. 1986 Apr;83(8):2699-703.

50.

The introversion of the immune response: a hypothesis for T-B interaction.

Leserman L.

Immunol Today. 1985 Dec;6(12):352-5. doi: 10.1016/0167-5699(85)90092-1.

PMID:
25291222

Supplemental Content

Loading ...
Support Center